Lithium Citrate — Competitive Intelligence Brief

Lithium Citrate (LITHIUM CITRATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: lithium. Area: Metabolic.

marketed lithium Glycogen synthase kinase-3 Metabolic Small molecule

Target snapshot

Lithium Citrate (LITHIUM CITRATE) — Hikma. Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lithium Citrate TARGET	LITHIUM CITRATE	Hikma	marketed	lithium	Glycogen synthase kinase-3	1980-01-01
Lithobid	lithium carbonate	Generic (multiple manufacturers)	marketed	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06
Lithium Carbonate	LITHIUM CARBONATE		marketed	lithium carbonate	Glycogen synthase kinase-3	1970-01-01
Lithium (LI)	Lithium (LI)	Weill Medical College of Cornell University	marketed	Mood stabilizer	Inositol monophosphatase, GSK-3 (glycogen synthase kinase-3)
Lithium Carbonate Pill	Lithium Carbonate Pill	Shanghai Mental Health Center	marketed	Mood stabilizer	Glycogen synthase kinase-3 (GSK-3), inositol monophosphatase
Lithium Augmentation	Lithium Augmentation	Centre for Addiction and Mental Health	marketed	Mood stabilizer / Augmentation agent	Inositol monophosphatase; protein kinase C; glycogen synthase kinase-3 (GSK-3)
Placebo plus Lithium	Placebo plus Lithium	Shanghai Mental Health Center	marketed	Mood stabilizer	GSK-3 (glycogen synthase kinase-3), inositol monophosphatase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (lithium class)

1. Hikma · 1 drug in this class